Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

Bullboard Posts

Post by R_J_on Jun 01, 2019 12:27pm

56 Views

Post# 29791254

End of Month - May 2019

End of the Month (EOM) report for May 2019.
-
AVXL closed on 05/31/2019 at US$2.89
AVXL closed on 04/30/2019 at US$2.97
AVXL closed on 03/29/2019 at US$3.05
-
This is a 2.7%, a 8-cent, loss for May.
This is a 85.3%, a $1.33, gain Year to Date..
-
S&P 500 Index, @ 2,752.0, lost 6.6% in May. [0.8% below its MA(200) @ 2,775.5]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's MA(200) ended May at $2.54
AVXL is now 13.8% above its MA(200).
-
News Releases on the AVXL Website in May
-
Use this link to see and read May’s News Release.
-
https://www.anavex.com/2019/04/
-
RJ

Bullboard Posts

Mining play provides exploration update